Genetic counselor Victoria M. Raymond was lead author of the study linking prostate cancer with Lynch syndrome.

Weighing The Risks

Prostate cancer risk rises in men with Lynch syndrome

issue 18 | spring/summer 2013

Men with the inherited genetic condition Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study led by researchers at the University of Michigan Comprehensive Cancer Center.

Lynch syndrome is linked to a higher risk of several types of cancer. People with Lynch syndrome have up to an 80 percent lifetime risk of colorectal cancer and are also more likely to develop endometrial, gastric, ovarian, urinary tract, pancreatic or brain tumors. Overall, about 1 in 440 people are carriers for the genetic mutation, making it one of the most common inherited cancer conditions.


The findings in prostate cancer have implications for screening younger men who may be at higher risk of the disease. Recent guidelines from the U.S. Preventive Services Task Force recommend against screening with PSA in men younger than 75 who do not have any symptoms.

"For men with an inherited risk factor for prostate cancer, they should still be thinking about prostate cancer screening. Our study is valuable for patients and physicians when weighing the risks and benefits of screening. We suggest men with Lynch syndrome might benefit from regular prostate cancer screening beginning at age 40," says lead study author Victoria M. Raymond, a certified genetic counselor with the University of Michigan’s Cancer Genetics Clinic.

“Our study is valuable for patients and physicians when weighing the risks and benefits of screening.”

Victoria M. Raymond


The researchers looked at 198 families who have a strong family history of cancer and were enrolled in registries at the University of Michigan Comprehensive Cancer Center or at Dana Farber Cancer Institute. These family registries included 4,127 men who were included in this analysis.

Among men with a mutation linked to Lynch syndrome, the researchers estimated their lifetime risk of prostate cancer to be 30 percent, compared to SEER data that puts lifetime risk among the general population at 18 percent. Men aged 20–59 who carried this mutation also faced a higher risk of prostate cancer than the general public, with a hazard ratio of 2.5.

Earlier studies have suggested that Lynch syndrome might play a role in inherited prostate cancer, but studies to date have been controversial.

"It’s been tricky to figure out if prostate cancer is really associated with Lynch syndrome. It’s a very common cancer," says Raymond. "When you see it occurring in families, it’s difficult to figure out if that’s because it’s associated with Lynch syndrome or just because it’s really common."

The current study uses a more rigorous statistical analysis and pulls from a larger number of people. This same method has previously linked Lynch syndrome to endometrial cancer and pancreatic cancer. Results of the study appeared in the Journal of Clinical Oncology.